文献速递前列腺癌

恩扎卢胺治疗非转移性去势抵抗性前列腺癌中PSA进展与影像学进展的关系

Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
PubMed 文献 · Eur Urol · 2020-10-01

该研究回顾性分析PROSPER试验中非转移性去势抵抗性前列腺癌(nmCRPC)患者,评估PCWG2定义的PSA进展对影像学或临床进展的预测价值。恩扎卢胺治疗组中,PSA进展者转移或死亡风险显著增加(HR 3.99),中位无转移生存期(MFS)为22.6个月,而无PSA进展者未达到。影像学进展时PSA较最低值中位升高仅1.4 ng/mL,提示任何PSA升高均需密切监测。

要点

  • 恩扎卢胺治疗nmCRPC,PCWG2定义的PSA进展与影像学进展风险显著相关。
  • 影像学进展时PSA较最低值中位升高仅1.4 ng/mL,提示微小升高即可能进展。
  • PCWG2的PSA进展阈值可能不足以预测影像学进展,需重新评估。

核心结论

  • 在恩扎卢胺治疗的nmCRPC患者中,PCWG2定义的PSA进展与影像学进展风险增加相关。
  • 影像学进展常发生在未达到PCWG2定义的PSA进展时,任何PSA升高均可能需更密切监测。

研究设计与样本

  • PROSPER试验(NCT02003924)的事后回顾性分析。
  • 纳入非转移性去势抵抗性前列腺癌(nmCRPC)男性患者。
  • 患者随机2:1接受恩扎卢胺160 mg/d或安慰剂,继续雄激素剥夺治疗。

主要发现

  • 恩扎卢胺组:PSA进展者 vs 无PSA进展者,转移或死亡风险HR 3.99(95%CI 2.95-5.41;p<0.0001)。
  • 恩扎卢胺组:无PSA进展者中位MFS未达到(NR;95%CI NR-NR),PSA进展者中位MFS 22.6个月(95%CI 21.9-29.0)。
  • 安慰剂组:PSA进展与MFS无显著关联(HR 1.72;95%CI 0.86-3.45;p=0.1)。
  • 安慰剂组:无PSA进展者中位MFS NR(95%CI 25.6-NR),PSA进展者中位MFS 18.3个月(95%CI 14.9-19.4)。
  • 影像学进展时PSA较最低值中位升高:恩扎卢胺组1.4 ng/mL,安慰剂组25.6 ng/mL。

关键数值与推荐

  • PSA进展采用PCWG2定义。
  • 主要结局为无转移生存期(MFS)。

临床怎么用

  • 恩扎卢胺治疗nmCRPC时,任何PSA升高均应考虑密切监测,即使未达PCWG2进展标准。
  • PCWG2的PSA进展阈值可能需要前瞻性重新评估。

局限性

  • 事后回顾性分析,非预设分析。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no universally accepted definition for prostate-specific antigen (PSA) progression. However, changes in PSA in patients with castration-resistant prostate cancer (CRPC) are used to inform treatment decisions. OBJECTIVE: To determine whether the Prostate Cancer Working Group 2 (PCWG2) definition of PSA progression is adequate to predict radiographic or clinical progression in enzalutamide-treated men with nonmetastatic CRPC (nmCRPC). DESIGN, SETTING, AND PARTICIPANTS: A post hoc, retrospective analysis of men with nmCRPC from PROSPER (NCT02003924) was performed. INTERVENTION: Continued androgen deprivation therapy; patients randomized 2:1 to enzalutamide 160 mg/d or placebo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metastasis-free survival (MFS) in men with and without PSA progression, defined by PCWG2, and PSA at the time of radiographic progression were assessed. RESULTS AND LIMITATIONS: As of June 28, 2017, in enzalutamide-treated patients, the risk of metastasis or death was increased significantly in those with PSA progression versus those without (hazard ratio [HR] 3.99; 95% confidence interval [CI], 2.95-5.41; p < 0.0001). Median MFS was not reached (NR; 95% CI, NR-NR) in patients without PSA progression and was 22.6 mo (95% CI, 21.9-29.0) in those with PSA progression. In placebo-treated patients, PSA progression was not significantly associated with MFS (HR 1.72; 95% CI, 0.86-3.45; p = 0.1). Median MFS was NR (95% CI, 25.6-NR) in patients without PSA progression and 18.3 mo (95% CI, 14.9-19.4) in those with PSA progression. The median PSA increase from nadir at the time of radiographic progression was 1.4 ng/mL in enzalutamide-treated men and 25.6 ng/mL for the placebo arm. CONCLUSIONS: In men with nmCRPC and rapidly rising PSA, radiographic progression often occurred without PCWG2-defined PSA progression, suggesting that any increase in PSA may warrant closer monitoring. While PCWG2-defined PSA progression was associated with radiographic progression in enzalutamide-treated men, our findings argue for prospective re-evaluation of this threshold. PATIENT SUMMARY: In this report, we looked at changes in prostate-specific antigen (PSA) in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer who no longer respond to testosterone-lowering treatment. We found that even very small changes in PSA while on treatment could be an early indication of disease progression and should trigger closer monitoring.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Saad F, Sternberg CN, Efstathiou E, et al. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Eur Urol. 2020. PMID: 33010985. doi:10.1016/j.eururo.2020.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。